Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amgen Inc. recently completed a clinical study titled A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE). The study aimed to evaluate the efficacy of rocatinlimab combined with topical treatments compared to a placebo in treating moderate-to-severe atopic dermatitis, using assessments like the Validated Investigator’s Global Assessment for Atopic Dermatitis and the Eczema Area and Severity Index.
The intervention tested was rocatinlimab, a drug administered via subcutaneous injection, designed to be used in combination with topical corticosteroids and/or calcineurin inhibitors. The study included two experimental groups receiving different doses of rocatinlimab and a placebo group, all receiving treatment every four weeks for 24 weeks.
This interventional study was randomized and sequential, with a double-blind design where both participants and investigators were unaware of group assignments. The primary purpose was treatment-focused, aiming to establish the efficacy and safety of the drug combination.
The study began on February 21, 2023, and was completed by its primary completion date. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and understanding its timeline in the context of drug development.
The completion of this study could influence Amgen’s stock performance positively if results show significant efficacy and safety, potentially enhancing investor confidence. This update positions Amgen competitively within the pharmaceutical industry, particularly in the dermatology sector.
The study is now completed, with further details available on the ClinicalTrials portal.